Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O14813

UPID:
PHX2A_HUMAN

ALTERNATIVE NAMES:
ARIX1 homeodomain protein; Aristaless homeobox protein homolog; Paired-like homeobox 2A

ALTERNATIVE UPACC:
O14813; A8K3N0; Q8IVZ2

BACKGROUND:
The Paired mesoderm homeobox protein 2A, known alternatively as ARIX1, Aristaless homeobox protein homolog, and Paired-like homeobox 2A, is instrumental in the specific expression of catecholamine biosynthetic genes. Its function as a transcription activator/factor is crucial for sustaining the noradrenergic phenotype, underscoring its importance in neurobiological processes.

THERAPEUTIC SIGNIFICANCE:
Given its association with congenital fibrosis of extraocular muscles type 2, a condition marked by significant ophthalmoplegia, the therapeutic potential of targeting Paired mesoderm homeobox protein 2A is immense. Exploring its role further could lead to groundbreaking treatments for ocular motility disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.